The Sitagliptin CVOT In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, 14,671 patients with type 2 diabetes and established cardiovascular disease were randomized to addition of sitagliptin or placebo to existing therapy for a median follow-up period of 3.0 years
Durham Peptides carries GHK-Cu individually (50mg) as well as the GLOW Blend (70mg) for researchers who want the convenience of a multi-peptide formulation
Enhanced Benefits of Zerona Treatment Skin Tightening Effect : Apart from reducing fat, Zerona also tightens loose skin, enhancing the bodys contour
What challenges do individuals face in accessing GLP-1 medications
Found naturally in the body, acetyl-l-carnitine supports the availability of acetyl-CoA, an important energy generating metabolite
Research Use Notice This compound is provided strictly for research purposes